# XARlabs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xarlabs

- Industry: Software
- Headquarters: London, UK
- Website: www.xarlabs.ai
- Total disclosed funding: $2.3M
- Latest round: Seed (Feb 10, 2025)
- Investors on record: 1

## About

Established in 2024 and based in London, UK, simXAR LTD, trading under the name, XARlabs, operates as a health technology platform that provides 3D modelling and immersive solutions for surgical planning, medical education, and clinical collaboration. In February 2025, XARlabs raised USD 2.3 million in seed funding led investor EKA Ventures. The firm as of January 2025, is led by its  founder and CEO, Ali Haddad.

XARlabs specializes in advanced mixed reality platforms, with its flagship offering being the simXAR technology. This platform is designed to enhance the training and rehearsal processes for medical professionals by providing highly detailed 3D simulations that replicate surgical environments. The simXAR technology integrates procedural rehearsal and patient consent tools, facilitating a comprehensive approach to surgical preparation that caters to diverse learning styles. Targeted primarily at healthcare institutions and medical educators, the technology is employed in various surgical scenarios, enabling users to engage in immersive learning experiences that improve precision and decision-making in surgical contexts. XARlabs operates on a global scale, serving markets in North America, Europe, and Asia, positioning it to address the needs of an international client base that includes hospitals, surgical training centers, and educational institutions.

XARlabs generates revenue primarily through a business-to-business model, providing its simXAR platform to healthcare facilities and training organizations. The company's transaction structure involves subscription agreements, where clients access the technology and tools for a specified period, alongside potential partnerships to facilitate broader adoption in surgical training environments.

The company plans to utilize the February 2025 funding to expand the international reach of its flagship product, simXAR, and enhance its mixed reality platform to advance surgical training, planning, and real-time visualization.

## Funding rounds

- Seed, Feb 10, 2025, $2.3M — Eka Ventures

## Investors

- Eka Ventures (https://capitalatlas.ai/funds/eka-ventures) — Seed